Sansure Biotech, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000043J1
CNY
19.93
-0.32 (-1.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Sansure Biotech, Inc.
Why is Sansure Biotech, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -23.58% and Operating profit at -52.58% over the last 5 years
2
The company has declared Negative results for the last 10 consecutive quarters
  • NET PROFIT(9M) At CNY 207.18 MM has Grown at -38.85%
  • DEBT-EQUITY RATIO (HY) Highest at -49.37 %
  • INTEREST(Q) Highest at CNY 6.1 MM
3
With ROE of 2.60%, it has a very attractive valuation with a 1.59 Price to Book Value
  • Over the past year, while the stock has generated a return of -17.20%, its profits have fallen by -49.9%
  • At the current price, the company has a high dividend yield of 4
4
Below par performance in long term as well as near term
  • Along with generating -17.20% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Sansure Biotech, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sansure Biotech, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Sansure Biotech, Inc.
-14.79%
0.24
37.49%
China Shanghai Composite
15.19%
1.01
14.58%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-23.58%
EBIT Growth (5y)
-52.58%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
0.29
Tax Ratio
11.45%
Dividend Payout Ratio
108.99%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
87.81%
ROE (avg)
18.63%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
61
Industry P/E
Price to Book Value
1.59
EV to EBIT
58.00
EV to EBITDA
24.67
EV to Capital Employed
2.03
EV to Sales
5.31
PEG Ratio
NA
Dividend Yield
4.01%
ROCE (Latest)
3.49%
ROE (Latest)
2.60%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -4.55% (YoY

NET SALES(Q)

Highest at CNY 472.65 MM

PRE-TAX PROFIT(Q)

Highest at CNY 112 MM

NET PROFIT(Q)

Highest at CNY 90.78 MM

EPS(Q)

Highest at CNY 0.16

-15What is not working for the Company
NET PROFIT(9M)

At CNY 207.18 MM has Grown at -38.85%

DEBT-EQUITY RATIO (HY)

Highest at -49.37 %

INTEREST(Q)

Highest at CNY 6.1 MM

Here's what is working for Sansure Biotech, Inc.
Net Sales
Highest at CNY 472.65 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Net Sales
At CNY 472.65 MM has Grown at 21.63%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit
Highest at CNY 112 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 90.78 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS
Highest at CNY 0.16
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost
Fallen by -4.55% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sansure Biotech, Inc.
Interest
At CNY 6.1 MM has Grown at 283.2%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at -49.37 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest
Highest at CNY 6.1 MM
in the last five periods and Increased by 283.2% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)